# Eli Lilly and Company (LLY) — Q4-2017 Earnings Results

**Report date:** 2018-01-31 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q4-2017

## Post-Earnings Brief

### Headline

Eli Lilly Beats on EPS, Stock Down 5.39%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.14 | N/A | +3.72% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's future prospects despite the lack of revenue guidance. They emphasized their commitment to innovation and market expansion.

**Key quotes:**

> Management highlighted ongoing investments in research and development.

> They noted a strong pipeline of products expected to drive future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Eli Lilly's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 5.39%, likely due to the absence of revenue figures and guidance, which left investors uncertain about future performance. The management's cautious tone may also have contributed to the stock's decline.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q4-2017_